These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7792038)

  • 21. Bone disease in renal failure. Clinical and histomorphometric studies.
    Nilsson P
    Scand J Urol Nephrol Suppl; 1984; 84():1-68. PubMed ID: 6393322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3.
    Madsen S
    Acta Med Scand Suppl; 1980; 638():3-120. PubMed ID: 6929650
    [No Abstract]   [Full Text] [Related]  

  • 23. [Renal osteodystrophy and growth in children undergoing CAPD].
    Ito T; Horiike S; Iitaka K
    Nihon Jinzo Gakkai Shi; 1991 Aug; 33(8):779-90. PubMed ID: 1770638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renal osteodystrophy in hemodialysis patients.
    Oda H; Yorioka N; Takemasa A; Shigemoto K; Harada S; Ito T; Masaki T; Yamakido M
    Hiroshima J Med Sci; 1995 Sep; 44(3):83-8. PubMed ID: 8567317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone mineral density among patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
    Pongchaiyakul C; Pongskul C; Ruengjui S; Sirivongs D
    J Med Assoc Thai; 2005 Oct; 88 Suppl 5():S40-5. PubMed ID: 16869106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bone mineral density in rural Thai adults living in Khon Kaen province.
    Pongchaiyakul C; Rojroongwasinkul N; Chotmongkol R; Kosulwat V; Charoenkiatkul S; Rajatanavin R
    J Med Assoc Thai; 2002 Feb; 85(2):235-44. PubMed ID: 12081125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone.
    Bro S; Brandi L; Olgaard K
    Nephrol Dial Transplant; 1996 Aug; 11(8):1586-91. PubMed ID: 8856216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
    Garnero P; Sornay-Rendu E; Chapuy MC; Delmas PD
    J Bone Miner Res; 1996 Mar; 11(3):337-49. PubMed ID: 8852944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparisons between oral and intraperitoneal 1,25-dihydroxyvitamin D3 therapy in children treated with peritoneal dialysis.
    Jones CL; Vieth R; Spino M; Ledermann S; Kooh SW; Balfe J; Balfe JW
    Clin Nephrol; 1994 Jul; 42(1):44-9. PubMed ID: 7923966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Osteopenia during long-term haemodialysis: response to vitamin D3 analogues.
    Muirhead N; Adami S; Fraser RA; Catto GR; Edward N; O'Riordan JL
    Proc Eur Dial Transplant Assoc; 1981; 18():567-72. PubMed ID: 6895786
    [No Abstract]   [Full Text] [Related]  

  • 31. Influence of 1 alpha-hydroxy vitamin D3 (0.25 micrograms/day) and calcium carbonate on patients with chronic renal failure at the predialytic stage.
    Okada K; Nagura Y; Takahashi S; Hatano M
    Nihon Jinzo Gakkai Shi; 1989 Jun; 31(6):657-60. PubMed ID: 2795995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Selected parameters of bone metabolism in hemodialyzed and peritoneally dialyzed patients].
    Małyszko J; Zbroch E; Wołczyński S; Myśliwiec M
    Przegl Lek; 2000; 57(12):711-3. PubMed ID: 11398592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum albumin and bone mineral density in healthy older men and women: the Rancho Bernardo Study.
    Lunde AV; Barrett-Connor E; Morton DJ
    Osteoporos Int; 1998; 8(6):547-51. PubMed ID: 10326059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers.
    Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
    Nephrol Dial Transplant; 2008 Nov; 23(11):3670-6. PubMed ID: 18579534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy.
    Muirhead N; Catto GR; Edward N; Fraser RA; O'Riordan JL; Papapoulos SE; Adami S
    Proc Eur Dial Transplant Assoc; 1980; 17():543-7. PubMed ID: 6972529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secondary hyperparathyroidism and risk factors in patients undergoing peritoneal dialysis in a tertiary hospital.
    Suwan N
    J Med Assoc Thai; 2011 Sep; 94 Suppl 4():S101-5. PubMed ID: 22043575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical study of concerning factors of decreased bone mineral content in hemodialysis patients].
    Kohara N
    Nihon Jinzo Gakkai Shi; 1991 Jun; 33(6):587-96. PubMed ID: 1920939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of 1,25(OH)2-vitamin D3 to separate 'types' on renal osteodystrophy.
    Coburn JW; Brickman AS; Sherrard DJ; Singer FR; Wong EG; Baylink DJ; Norman AW
    Proc Eur Dial Transplant Assoc; 1977; 14():442-50. PubMed ID: 600961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The evolution of renal osteodystrophy in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
    Calderaro V; Oreopoulos DG; Meema HE; Ogilvie R; Husdan H; Khanna R; Quinton C; Murray T; Carmichael D
    Proc Eur Dial Transplant Assoc; 1980; 17():533-42. PubMed ID: 6787584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The effect of 1,25(OH)2D3 on bone mineral content in senile osteoporosis--a dose-finding study].
    Shiraki M; Ito H; Orimo H
    Nihon Naibunpi Gakkai Zasshi; 1989 Nov; 65(11):1253-63. PubMed ID: 2591609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.